

## DAFTAR PUSTAKA

- Podschun R, Ullmann U, 1998. *Klebsiella* spp. As nosocomial pathogens: Epidemiology, taxonomy, Typing methods, and pathogenicity factors. *Clinical Microbiology reviews*, Oct: p.589-603
- Adysaputra SA, Rauf, AM, Bahar B. 2009. Patterns and prevalence of nosocomial microbial infection from ICU patients, Wahidin Sudirohusodo Hospital. Makassar; Hasanudin university Press. *Indonesian journal of medical science*. Vol 2. No.2.p.67-70
- Tennant, I., Harding, H. 2005. Microbial isolates from patients in an intensive care units and association risk factors, *West Indian medical journal*, vol 54, no.4.
- Hidayat, Irmasuri, Kurnia, N., Hardiyanto Y, 2014. Peta kuman dan resistensi terhadap berbagai antibiotik di RSUD dr. H. Abdul Moeloek Lampung.
- Loureiro MM, Moraes BA, Mendonca VL, Quadra MR, Pinheiro GS, Asensi MD, 2001. Molecular epidemiology of ESBL producing *Klebsiella pneumoniae* isolated from neonatal ICU patients involved in hospital infection cases in Rio de Janeiro, Brazil. *Rev Latinoam Microbiol*; 43(2): 88-95
- Weber M, Handy F, 2010. Situasi Pneumonia di Indonesia dalam: *Buletin Jurnal Epidemiologi*. Kemenkes RI
- Tambunan, 2011. Angka kejadian infeksi nosokomia di bagian Perinatologi RS Harapan Kita. *Jurnal Kedokteran*.
- Nathisuwan S, Burgess DS, Lewis II JS, 2001. Extended spectrum  $\beta$ -lactamases: epidemiology, detection and treatment. *Pharmacotherapy* 21(80) : 920-928
- Bradford PA, 2001. ESBL in the 21st Century: Characterization, epidemiology and detection of this important resistance threat, *Clinical Microbiology reviews* ;933-935
- Paterson DL, Bonomo RA, 2005. Extended-spectrum  $\beta$ -lactamase: a clinical update. *Clinical Microbiology Reviews* ; 657-686
- Tumbarello M, Sali M, Trecarichi EM, 2008. Bloodstream infections caused by extended spectrum  $\beta$ -lactamase producing *Escherichia coli*: Risk factors for inadequate initial antimicrobial therapy. *Antimicrob Agents Chemother* ;52:3244-3255

- Sharma J, Meera S, palap R. 2009. Detection of TEM and SHV in *Escherichia coli* and *Klebsiella pneumoniae* isolates in a tertiary care hospital from india. *Indian Journal med Res.* 132: 332-336
- Taslima Y. 2012. Prevalence of ESBL among *E.coli* and *Klebsiella sp* in a tertiary care hospital and molecular detection of important ESBL producing genes by multiplex PCR. Departement microbiology and immunology Mymensingh Medical college, Mymensing. Banglades. P.66-68
- Emery CL, Weymounh LA. 1997. Detection and clinical significance of Extended spectrum in tertiary care medical centre. *J. Clin. Microbiol.* 35: 2061-67
- Bell JM, Turnidge JD, Gales AC, Pffaller MA, Jones RN, 2002. Prevalence of ESBL producing clinical isolates in the Asia Pasific region and South Africa: result from SENTRY Antimicrobial surveillance program (1998-99). *Diagnosis microbiology and infectious disease*; 42: 193-198
- Kuntaman K, Mertaniasih NM, Purwanta M, Hadi U, Vebrugh HA, 2005. The antimicrobial susceptibility pattern of extended spectrun betalactamase producing *Escherichia coli* in Surabaya, Indonesia. Denmark: ESCMID Copenhagen.
- Juwono, 2012. Identification of SHV gene among Enterobacteriaceae produce extended spectrum betalactamase. Departement of Microbiology faculty of Medicine University of Sriwijaya. Moh. Hoesin General Hospital palembang.
- Irawan D, Hamidah, Purwati, Triyono EA, Bramantono, Arfianto V, et al. 2012. Profil penderita sepsis akibat bakteri penghasil ESBL. *Jurnal Penyakit Dalam*, vol 13. 2012. Departemen Ilmu Penyakit Dalam FK Unair/RSUD dr. Soetomo Surabaya
- AL-Jasser AM. 2006. Extended spectrum beta lactamases: Global problem. *Kuwait medical Journal.* 38(3): 171-185
- Bermudes HC, Arpin FJ, El Harrif C, Bebear CQ. 1997. Molecular epidemiology of an outbreak due to extended-spectrum beta lactamase-producing Enterobacteriaceae in a French hospital. *Eur.J.Clin. Microbiol. Infect. Dis.* 16:523-529
- Cotton MF, Wasserman E, Pieper CH. 2000. Invasive disease due to extended spectrum betalactamases producing *klebsiella pneumoniae* in a neonatal unit: the possible role of cockroaches. *J Hosp Infect* 44: 13-7
- Sheng WH, Badal RE, Hsueh PR. 2013. Distribution of ESBLs, AmpC betalactamases, and carbapenemases among Enterobacteriaceae isolates

causing intra abdominal infections in the Asia-Pacific region: results of the study for monitoring antimicrobial resistance trends. *Antimicrobial agents and chemotherapy*. Vol 57. P.2981-2988

Severin JA, Mertaniasih NM, Kuntaman K, et al. 2010. Molecular characterization of ESBLs in clinical E.coli and Klebsiella pn isolates from Surabaya Indonesia. *J.Antimicro Chemother*. Vol 65. P.464-469

Chen JH, Siu LK, Fung CP, Lin JC, Yeh KM, Chen TL, Tsai YK, et al, 2010. Contribution of outer membran protein K36 to antimicrobial resistance and virulence in Klebsiella pneumoniae. *J Antimicrobial chemother*. 65; p.986-990.

Tsai YK, Fung CP, Lin JC, Chen JH, Chang FY, Chen TL, Siu LK, Apr 2011. Klebsiella pneumoniae outer membran porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. *Antimicrobial agents and chemotherapy*. Vol 55(4); p.1485-93.

Jiang MJ, Zhao SP, Li JM, February 2012. Resistance of  $\beta$ -Lactamase producing Klebsiella pneumoniae to Imipenem with OmpK36 loss. *African Journal of microbiology research*. Vol 6(6); p.1312-17.

Sanchez AD, Martinez LM, Alles SH, Conejo MC, Pascual A, Tomas JM, Alberti S, Benedi. 2003. Role of Klebsiella pneumoniae OmpK35 porin in antimicrobial resistance. *Antimicrobial agents and chemotherapy*. Vol 47(10); p.3332-35.

Alles SH, Conejo MC, pascual A, Tomas JM, Benedi VJ, Martinez LM, 2000. Relationship between outer membrane alterations and susceptibility to antimicrobial agents in isogenic strains of Klebsiella pneumoniae. *Journal of Antimicrobial chemotherapy*, 46;p.273-77.

Yang D, Guo Y, Zhang Z. 2009. Combined porin loss and extended spectrum  $\beta$ -lactamase production is associated with an incasing Imipenem minimal inhibitory concentration in clinical Klebsiella pneumoniae strains. *Curr microbiol* 58; p.366-70.

Landman D, Bratu S, Quale J, 2009. Contributing of OmpK36 to carbapenem susceptibility in KPC producing Klebsiella pneumoniae. *Journal of medical microbiology*. 58; p.1303-08.

Wang XD, Cai JC, Zhou HW, Zhang R, Chen GX. Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid mediated  $\beta$ -lactamase production and OmpK36 porin deficiency. *Journal of medical Microbiology* 58; p.1196-1202.

- Aravin L, 1998. An evolutionary classification of the metallo betalactamase fold proteins. Tersedia dari: <http://www.bioinfo.de/isb/1998/01/0008>
- Drawz SM, RA B, 2010. Three decades of betalactamase inhibitors. *Clinical Microbiol reviews*;23(1):160-201
- Weldhagen G, Poirel L, Nordmann P, 2003. Ambler class A ESBL in *Pseudomonas aeruginosa*: novel developments and clinical impact. *Antimicrobial agents and chemotherapy*;2: 2385-2392
- Bush K, Jacoby GA, 2010. Update functional classification of beta-lactamases. *Antimicrob agents Chemother*; 54(3):969-76
- Chaudhary U, Agarwal R, 2004. ESBL an emerging threat to clinical therapeutics. *Indian Journal of Medical Microbiology*;22(2): 75-80
- Jacoby GA, Price LS, 2005. The new Betalactamases: Mechanism of disease. *Eng Journal Med*; 352: 380-391
- Quennan Am, Bush K, 2005. Carbapenemases; the versatile b-lactamases in: *Clinical Microbiology reviews*: 450-458
- Hall BG, Barlow M, 2004. Evolution of the serine beta-lactamases: past, present and future. *Drug resist update*;7(2): 111-123
- Mahon CR, Manuselis G Jr, 1995. Enterobacteriaceae in ; Text book diagnostic microbiology, 1st edition. Philadelphia London Toronto Montreal Tokyo: W.B Saunders Company.
- Schembri MA, Blom J, Krogfelt KA, Klemm P, 2005. Capsule and fimbria interaction in *Klebsiella pneumoniae*. *Infection and immunity*; 73(8):4626-4633
- Sahly H, Venezia SN, Roesler L, Hay A, Carmeli Y, Podschun R, Hennequin C, Forestier C, Ofek I, 2008. *Antimicrobial agents and chemotherapy*; 52(9): 3029-3034
- Rice L. 2001. Evolution and clinical importance of extended spectrum  $\beta$ -Lactamases. *Chest*. Vol 119; p.391-96.
- Romero IS, Asensio A, Oteo J, Algarra MM, Isidoro B, Vindel A, Avello JA, October 2011. Nosocomial outbreak of VIM-1 producing *Klebsiella pneumoniae* isolates of multilocus sequence type 15: molecular basis, clinical risk factors and outcome. *Antimicrobial agents and chemotherapy*. P.420-427.

- Nordmann P, Poirel L, 2002. Emerging carbapenemase in Gram negative aerobs. *Clin Microbiol Infect*;8(6):321-331
- Brunton L, Parker K, Blumenthal D, Buxton I, 2008. Goodman and Gilman's manual of pharmacology and therapeutics. New York Mc Graw Hill Medical; 728-750
- Papp Wallace KM, Endimiani A, Taracila MA, Bonomo RA, 2011. Minireview Carbapenems: past, present, and future. *Antimicrob agents chemother*; 55(11):4943-4960
- Poole K, 2004. Resistance to betalactam antibiotics. *Cell Mol Life Sci*;61(17):2200-2223
- Wilke MS, Lovering AL, NC.S, 2005. Beta lactam antibiotic resistance: a current structural perspective. *Current Opinion in Microbiology*; 8:525-533
- Hopley L, JV S, 2000. Mechanism of resistance to antimicrobials (update 24 Oktober 2006) Tersedia dari <http://www.anaesthetics.com/icu/infect/F.index.htm//resist.htm>
- Pratt C. K C, 2004. Bacterial drug resistance. Wiley. Tersedia dari [http://www.wiley.com/college/pratt/0471393878/instructor/activities/bacterial\\_drug\\_resistance/idex.html](http://www.wiley.com/college/pratt/0471393878/instructor/activities/bacterial_drug_resistance/idex.html)
- Samaha-Kfoury JN, Araj GF, 2003. Recent development in beta lactamase and ESBL. *BMJ*; 22(327): 1209-1213
- Coyle MB, 2005. Manual of antimicrobial susceptibility testing. American Society for Microbiology
- Nikaido H, 2003. Molecular basis of bacterial outer membrane permeability revisited. *Microbiology and Molecular Biology Reviews*; 67(4): 593-656
- De E, Basle A, Jaquinod M, Saint N, Mallea M, Molle G, Pages JM, 2001. A new mechanism of antibiotic resistance in Enterobacteriaceae induced by a structural modification of the mayor porin. *Molecular Microbiology*; 41(1):189-198
- Alles SH, Albert S, Alvarez D, Sanchez AD, Martinez LM, Gil J, Tomas JM, Benedi VJ, 1999. Porin expression in clinical isolates of *Klebsiella pneumoniae*. *Microbiology*; 145:673-679

- Pages JM, James CE, Winterhalter M, 2008. The porin and the permeating antibiotic: a selective diffusion barrier in Gram negative bacteria. *Nature reviews*; 6:893-903
- Perry JD, Naqvi Shi, Mirza IA, Alizai SA, Hussain A, Ghirardi S, et al, 2011. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. *J Antimicrob Chemother*; 66: 2284-2294
- Dortet L, Poirel L, 2014. Worldwide dissemination of the NDM-type carbapenemase in gram negative bacteria. *Biomol Research International*
- Van Hall MAL, Fluit Ac, Paauw A, Box ATA, 2002. Evaluation of the E-test ESBL and the BD phoenix, vitex I and vitex 2 automated instruments for detection of ESBL in multiresistant *E. coli* and *Klebsiella* spp. *J. Clinical Microbiol*; 3703-3711
- Blomberg B, et al. High rate of fatal cases of pediatric septicemia caused by gram negative bacteria with extended-spectrum beta-lactamase in dar salam, Tanzania. *J Clin Microbiol* ; 43(2): 745-749
- Colodner R, Raz R, 2005. Extended spectrum beta-lactamases ; the end of cephalosporins ? *IMAJ*; 7(3); 336-338

